Wolters Kluwer Health, a leading global provider of information for healthcare professionals and students, announced today that it has partnered with Philips Clinical Informatics TASY electronic health records (EHR) provider to improve ease of use and encourage greater adoption of medication decision support throughout Brazil. TASY is the first system used in Brazil to integrate Wolters Kluwer Clinical Drug Information drug data into its latest EHR release. With sophisticated drug data to power its medication, interactions and allergy screening functionality, TASY is creating an unprecedented advancement in efficiency in Brazilian healthcare.

Despite broad adoption of EHR solutions in Brazil, clinical decision support modules traditionally have not included the necessary drug data required to support screening functionality, forcing Brazilian pharmacists to build and enter their own drug information and interactions data. The newest TASY software offers up to eight clinical screening modules from Medi-Span®, an industry-leading Wolters Kluwer drug data solution. These include drug interactions, drug allergy, duplicate therapy, drug-disease contraindication, and dose range screening. With a strong foundation of easy-to-implement drug data integrated within EHR functions, TASY customers will be able to employ medication decision support that is more extensive, more detailed, and more current than what is commonly available in Brazil.

“The computerization of the healthcare processes, through electronic medical records and prescriptions, significantly increased the quality and safety of patient care,” said Ana Luiza Oliveira, head of Sales, Marketing and Services for Philips Clinical Informatics Latin America, “When we activate the simultaneous use of clinical decision support tools, we create the opportunity to increase even more the efficacy and efficiency of the treatment. Wolters Kluwer Health is a company with products of known reputation in this area of knowledge, and it is with pleasure that we are making the integration thereof available within our Philips TASY system.”

“Philips TASY is launching nothing short of a new era in Brazilian healthcare, and Wolters Kluwer Clinical Drug Information is proud to be a partner in these revolutionary efforts,” stated Steven Kerscher, Vice President & General Manager, Clinical Drug Information, Wolters Kluwer Health, Clinical Solutions. “With easier implementation of drug data within the EHR, healthcare professionals will have efficient access to cutting-edge medication decision support to promote safe decision making, a reduction in adverse drug events, and an overall enhancement of patient care.”

About Wolters Kluwer Health
Wolters Kluwer Health is a leading global provider of information, business intelligence and point-of-care solutions for the healthcare industry. Serving more than 150 countries worldwide, clinicians rely on Wolters Kluwer Health’s market leading information-enabled tools and software solutions throughout their professional careers from training to research to practice. Major brands include Health Language®, Lexicomp®, Lippincott Williams & Wilkins, Medicom®, Medi-Span®, Medknow, Ovid®, Pharmacy OneSource®, ProVation® Medical and UpToDate®.

Wolters Kluwer Health is part of Wolters Kluwer, a market-leading global information services company. Wolters Kluwer had 2013 annual revenues of €3.6 billion ($4.7 billion), employs approximately 19,000 people worldwide, and maintains operations in over 40 countries across Europe, North America, Asia Pacific, and Latin America. Wolters Kluwer is headquartered in Alphen aan den Rijn, the Netherlands. Its shares are quoted on Euronext Amsterdam (WKL) and are included in the AEX and Euronext 100 indices. Wolters Kluwer has a sponsored Level 1 American Depositary Receipt program. The ADRs are traded on the over-the-counter market in the U.S. (WTKWY).

Follow our official Twitter handle: @WKHealth.